Eventually the patentdatabase becomes rich enough with prior art to reach an equilibrium, but the errors in the interim produce a batch of legacy patents that never should have issued.
They are tied to greater needs such as the need for a global drug patentdatabase to facilitate access to safe, cheap generic drugs that would help to undercut the black market.